Chitosan is a family of glucosamine and N-acetyl glucosamine polysaccharides with poorly understood immune modulating properties. Here, functional U937 macrophage responses were analyzed in response to a novel library of twenty chitosans with controlled degree of deacetylation (DDA, 60e98%), molecular weight (1 to >100 kDa), and acetylation pattern (block vs. random). Specific chitosan preparations (10 or 190 kDa 80% block DDA and 3, 5, or 10 kDa 98% DDA) either induced macrophages to release CXCL10 and IL-1ra at 5e50 mg/mL, or activated the inflammasome to release IL-1b and PGE 2 at 50e150 mg/mL.
Introduction
Chitosan represents a family of a linear polysaccharide of b-O-(1e4)-linked glucosamine (GlcN) with variable content of N-acetyl glucosamine (GlcNAc). Chitosan is used in medical devices for hemostasis and regenerative medicine through mechanisms involving macrophage immune responses that have yet to be thoroughly elucidated [1e3] . To fully exploit the potential of this biomaterial polymer in regenerative medicine, its immunological properties should be thoroughly understood. Despite multiple studies that investigated macrophage responses to chitosan [3e14], current models are unable to explain why a given chitosan may elicit pro-or anti-inflammatory responses in macrophages. For example, chitosan has been shown to be a potent activator of the inflammasome [4, 5] , and can promote the release of proinflammatory cytokines Interleukin-1b (IL-1b) [4e6], Tumor Necrosis Factor (TNF) and chemokines associated with M1 macrophage polarization [6, 8] . Conversely, chitosan can also elicit antiinflammatory M2 macrophages [3, 11] , and stimulate the release of anti-inflammatory cytokines Interleukin-1 receptor antagonist (IL-1ra) and IL-10 [6, 10] . Others have also reported that certain types of chitosan are relatively immunologically inert [13, 14] . Across these studies, chitosans of varying origins, structural properties and purities were used. What is lacking at this time is a structure-function model that can be used to predict macrophage responses to chitosan according to its 3 main molecular characteristics: molecular weight, degree of deacetylation (DDA), and acetylation pattern.
Chitosan is produced by chemical deacetylation of chitin (GlcNAcb1-4) n [15] , leading to chitosan preparations with a GlcN content or DDA that ranges from 50 to 100%. In chitosans produced by this approach, the remaining GlcNAc residues are arranged in block, or clusters that are distributed heterogeneously along the chitosan chain [16] . Chitosan may also be produced with a random, homogeneous distribution of GlcNAc residues by treating fully deacetylated chitosan (GlcNb1-4) n, with acetic anhydride which reacetylates chitosan to specific DDA levels [17, 18] . Chitosan can also be depolymerized with nitrous acid to target molecular weights with acceptable polydispersity (PDI, weight-average molecular weight (M w )/number-average molecular weight (M n )) [19] . These methods can be used to produce chitosans with controlled structural features.
In a previous study, we analyzed the effects of a 132 kDa, 82% DDA, block-acetylated chitosan on the release of multiple pro-and anti-inflammatory cytokines, chemokines and growth factors in M0, M1 and M2-polarized U937 human macrophages. In nonpolarized macrophages, we found that chitosan selectively induced the release of a pro-inflammatory cytokine (IL-1b), a mesenchymal stem cell chemokine (CXCL10) and an antiinflammatory cytokine (IL-1ra) [6] . CXCL10 release was mediated by STAT-1 signaling and triggered in a delayed fashion by this 82% DDA chitosan. By contrast, 128 kDa 98% DDA chitosan failed to induce CXCL10 release for reasons that remain unclear [6] . 82% DDA chitosan-enhanced IL-1ra release was shown to be independent of paracrine IL-4, IL-10 signaling and IL-1b release [6] , suggesting that this effect is mediated by signaling pathways that remain to be determined. Furthermore, these findings also raise the possibility that chitosan structural properties can be tailored to elicit specific cytokine responses without eliciting others, such as inducing IL-1ra release without stimulating the release of IL-1b. The purpose of this study was to understand the mechanisms behind chitosan-induced cytokine production, in non-polarized macrophages.
Several studies have compared macrophage responses to 2 or 3 chitosans with different DDA [6, 11] , or different molecular weight [6, 12, 13] . A systematic and comprehensive study of pro-and antiinflammatory macrophage responses to a library of chitosans with distinct DDA and a comprehensive range of molecular weights is currently lacking. In this work, we generated a library of twenty different chitosans, with DDAs of 60, 80 and 98%, discrete numberaverage molecular weights (M n ) of 1 to over 100 kDa, with block or random acetylation patterns. This library was used to identify the minimal structural properties required for chitosan to stimulate macrophages to produce IL-1ra, CXCL10, IL-1b and Prostaglandin E 2 (PGE 2 ). These 4 factors were intended to serve as markers of chitosan-induced anti-inflammatory (IL-1ra), chemokine (CXCL10) or pro-inflammatory (IL-1b, PGE 2 ) responses in non-polarized U937 cells [6] . We then investigated the cellular mechanisms that lead to distinct cytokine responses and identified lysosomal disruption and IFN-beta (IFN-b) as the paracrine signaling pathway responsible for enhanced release of IL-1ra and CXCL10. 
Material and methods

Reagents
RPMI
Generation of the chitosan library
Chitosans (endotoxin units <500 EU.g
À1
, protein content <0.2%, heavy metals < 5 ppm) with 82% DDA, block acetylation, and M n 188 kDa (termed 80-190K-B), or 98% DDA and M n 113 kDa (termed 98e110K) were provided by BioSyntech (now Smith & Nephew, Mississauga, ON, Canada). 98% DDA and 80% DDA block-acetylated chitosans with target M n of 1, 3, 5 or 10 kDa were obtained through nitrous acid depolymerisation of the 98e110K and 80-190K-B chitosan, respectively, as previously described [19] . 60 and 80% DDA random-acetylated chitosans were generated from a starting chitosan (89.6% DDA and M n 151 kDa) that was deacetylated to 98% DDA using two consecutive hot alkaline treatments (25% NaOH (w/ v), 110 C, 30 min), then nitrous acid-depolymerized to target M n of 1, 3, 5 or 10 kDa. The 98% DDA chitosans with different M n were reacetylated to 60 or 80% DDA using acetic anhydride as previously described [18] . The depolymerisation and reacetylation reactions were stopped by addition of 1 M NaOH until alkaline pH was reached. Alkaline-insoluble chitosans above 10 kDa precipitated and were extensively washed in double-deionized water (ddH 2 O) by repeated centrifugation and resuspension until the supernatant reached neutral pH. Chitosans below 10 kDa were dialyzed (Biotech CE MWCO 100e500 Da, Spectrum Laboratories, CA, USA) five times against ddH 2 O over 48 h. Free base chitosans were flash-frozen in liquid nitrogen and freeze-dried. Selected chitosans were labeled to 0.5% mol RITC per mol chitosan as previously described [20] . All reactions were performed using depyrogenized glassware and endotoxin-free reagents. Chitosans were characterized for DDA, M n and weight-average molecular weight (M w ) using 1 H NMR and GPC as described previously [21, 22] . PDI was calculated as M w /M n . Chitosans were solubilized at 5 mg mL À1 in dilute HCl (resulting in 90% protonation), 0.22 mm filter-sterilized and kept at À80 C until use.
Macrophage differentiation and chitosan stimulation
All experiments involving human cell lines were carried out using institutionally approved protocols. U937 cells (ATCC # CRL-15932.2) were purchased from ATCC (Manassas, VA, USA), were maintained and differentiated to macrophages as described previously [6] . Briefly, U937 macrophages were differentiated in RPMI-1640 supplemented 10% FBS and 100 nM PMA for 72 h, manually resuspended, and seeded at 1 Â Macrophage CM was analyzed by ELISA for IL-1b, IL-1ra, CXCL10 and PGE 2 concentration according to the manufacturer's instructions. Leakage of cytosolic Lactate dehydrogenase (LDH) into the macrophage CM was determined against an LDH standard curve using a colorimetric LDH assay (Clontech, Mountain View, CA, USA). Cytotoxicity was reported as the percentage of LDH leakage in the CM ¼ (LDH activity in the CM of the sample)/(total LDH activity in the cell lysate and CM of control non-stimulated cells).
Immunoblotting
For analyses of STAT-1 and STAT-2 phosphorylation, cells were rinsed in cold PBS and lysed on ice in buffer containing 50 mM Tris, 150 mM NaCl, 2 mM Na 3 VO 4 , 10 mM NaF, 1% Triton-X 100 and protease inhibitors. For analysis of LC3 expression, cells were rinsed in cold PBS and lysed on ice in buffer containing 10 mM Tris, 150 mM NaCl, 0.04% Igepal CA-630, 2 mM EDTA, 0.5% sodium deoxycholate, 2 mM PMSF and protease inhibitors. Lysates were cleared by centrifugation at 21,000 g and kept at À80 C until use. 40 mg of protein was separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred to PVDF membranes. Membranes were blocked for 1 h in 5% w/v BSA in Trisbuffered saline with Tween-20, probed overnight at 4 C with primary antibody, and incubated with HRP-conjugated secondary antibodies for 1 h. Bands were detected using a chemiluminescent system (ECL, GE Healthcare, Baie d'Urfe, QC, Canada). b-Actin was used as a loading control. Band densitometry was carried out using Image J.
Immunohistofluorescence of Galectin-3, LC3 and confocal microscopy analyses
Macrophages were seeded in 8-chamber Labteks and stimulated with the 98-10K-RITC or 80-10K-R-RITC chitosans for 6, 10 or 18 h in presence or absence of 100 nM bafilomycin in medium with 100 nM PMA. Following stimulation, cells were fixed in ice-cold methanol for 15 min, incubated 1 h in 5% normal donkey serum/0.3% Triton-X 100/PBS, followed by overnight incubation at 4 C with 5 mg/mL anti-Galectin-3 and 0.1 mg/mL Alexa Fluor 647-conjugated anti-LC3A/B, then further incubated with Alexa Fluor 488-conjugated donkey anti-mouse antibodies to detect mouse monoclonal antiGalectin-3 for 1 h at room temperature. After washes in PBS, cells were counterstained with Hoechst 33342 and mounted in Mowiol.
Confocal imaging was performed using an Olympus FV1000 microscope using a 40Â objective. Fluorophore signal detection was performed using sequential excitation/emission bandwith 405 nm/425e475 nm (Hoechst 33342), 488 nm/500e530 nm (Alexa Fluor 488), 543 nm/555e625 (RITC), 635 nm/650 nm (Alexa Fluor 647). Imaged cells were analyzed for the presence of Galectin-3/ chitosan structures (GCS), which were identified as large intracellular punctated structures greater than 1.7 mm in diameter where RITC-chitosan and Galectin-3 were found to colocalize. For each condition, four random fields were analyzed per Labtek chamber and averaged to produce N ¼ 4 measures per condition from 4 independent cultures.
Flow cytometry analysis
Macrophages were stimulated with 2.5 mM LLoME, 5 or 50 mg/ mL 98-10K or 80-10K-R chitosan for 24 h. Cells were then stained with 100 nM LysoTracker for 2 h according to the manufacturer's instruction, washed, and analyzed using a FACSCalibur flow cytometer. Twenty thousand events were analyzed and data are reported as mean fluorescence intensity (MFI). The experiment was repeated in three independent cultures to generate N ¼ 3 measures.
Statistical analyses
Data are shown as mean ± standard error of the mean. Statistical analyses were performed using Statistica (Statsoft, Tulsa, OK, USA). The Factorial ANOVA General Linear Model (GLM) with Fisher's Least Square Difference post-hoc analysis was used to determine differences in cytokine release, PGE 2 generation, and LDH leakage due to chitosan type and dose level as the categorical predictors (N ¼ 4 independent cultures). The GLM with Fisher's Least Square Difference was used to determine differences in cytokine concentration, pSTAT-2/STAT-2 ratios, LC3-II/b-Actin band density, Lysotracker MFI, and GCS number as a function of treatment condition (98-10K chitosan, 80-10K-R chitosan, bafilomycin, chloroquine, neutralizing antibodies or PGE 2 ) (N ¼ 3 to 4 independent cultures).
Results
Characterization of the chitosan library for structural features
Chitosan DDA was determined using the ratio of 1 H NMR peaks for H1D (5.2 ppm) and HAc (2.3 ppm) as previously assigned ( Fig. 1 ) [22] . In comparison to the high molecular weight chitosans, proton spectra of the low molecular weight chitosans (below 5 kDa) showed additional peaks that were attributed to either protons on the 2,5-anhydro-D-mannose (M-unit) on the reducing end of the chitosan chain (3 peaks at 5.35, 4.5, 4.4 ppm) [23] , or protons on a by-product of nitrous acid depolymerisation, hydroxymethyl furfural (HMF) (4 peaks at 9.7, 7.8, 6.9, 4.9 ppm) ( Fig. 1 ) [24] . The library on average was within 1% (80%, 98%) or 5% (60%) of the target DDA. Gel permeation chromatography (GPC) analysis confirmed that the chitosan library was consistent with the target M n , with a PDI ranging from 1.2 to 2.5 (Table 1) . For simplicity, the chitosans used in this study were termed according to the nomenclature DDA-M n -B (block-acetylated) or DDA-M n -R (random-acetylated) ( Table 1) .
3.2. 98% DDA and 80% DDA block-acetylated chitosan stimulate differential IL-1ra/CXCL10 and PGE 2 /IL-1b release in a dosedependent manner
Using a 4-analyte factor array consisting in IL-1ra, CXCL10, IL-1b and PGE 2 , two mutually exclusive cytokine response patterns were observed depending on the chitosan and dose. At lower dose levels (5, 50 mg/mL), 10e110 kDa 80% DDA block and 3e10 kDa 98% DDA chitosans induced CXCL10 and IL-1ra release ( Fig. 2A and B) . Paradoxically, chitosan induction of CXCL10 and IL-1ra tapered off as the dose was increased. At the highest chitosan dose (150 mg/ mL), all 98% DDA chitosans over 3 kDa induced inflammasome activation, which led to increased IL-1b and PGE 2 release (Fig. 2C  and D) . IL-1b and PGE 2 release intensified as the molecular weight and dose of the >3 kDa 98% DDA chitosans increased (Fig. 2C and D ). Random-acetylated chitosans and 1 kDa oligomers failed to induce any significant release of cytokines or PGE 2 (Fig. 2) . In control cultures, IL-4 stimulated macrophages produced very high levels of IL-1ra compared to chitosan, and suppressed low-level baseline release of IL-1b (Fig. S1A) . IFN-g induced high levels of CXCL10, at 20-fold higher levels than the optimal dose of 98-10K chitosan (Fig. S1B) , and slightly higher IL-1b over baseline. LPS was the only factor that induced IL-1b and PGE 2 , and in addition induced the release of CXCL10 and even higher levels of IL-1ra than IL-4 (Figs. S1C and S1D). These data showed that chitosan-induced cytokine responses were distinct from those induced by IFN-g, IL-4 or endotoxin. Therefore, more experiments were needed, to understand how selected chitosans at different doses could induce U937 macrophages to release either CXCL10 and IL-1ra, or IL-1b and PGE 2 .
Cell cytotoxicity of the different chitosans and doses was determined by measuring LDH activity in the culture medium. LDH is a cytosolic enzyme released into the culture medium following cell death. LDH leakage induced by the library was found to parallel the level of IL-1b released to the medium, where the 98% DDA chitosans above 3 kDa at higher doses induced the most cell death (Fig. S2) . Induction of IL-1b release, PGE 2 generation, and LDH leakage each correlated with chitosan tendency to precipitate and aggregate, as measured by chitosan turbidity at neutral pH (R 2 ¼ 0.69 to 0.82, p < 0.001, Fig. S3 ).
In summary, our 4-analyte factor array showed that a sub-set of structurally distinct chitosans can induce the release of two distinct cytokine signatures: one signature consisted of co-induction of IL1ra and CXCL10 at low chitosan doses (R 2 ¼ 0.72, p < 0.001, 
Chitosan induces a type 1 IFN response to stimulate the release of IL-1ra and CXCL10
We previously reported that 132 kDa 82% DDA, block-acetylated chitosan induced delayed STAT-1 phosphorylation and CXCL10 secretion in U937 macrophages starting at 10 h post-stimulation [6] . In line with these observations, inhibition of translation or transcription prevented 80-190K-B chitosan from inducing STAT-1 phosphorylation (Fig. S5A ), indicating that de novo gene expression was essential for the chitosan-induced STAT-1/CXCL10 response. Both type II (IFN-g) and type I IFN (IFN-a/b) can induce STAT-1 factor activation leading to CXCL10 expression, however only IFN-a/b can induce STAT-2 phosphorylation [25] . We therefore used STAT-2 phosphorylation as a way to test whether chitosan was inducing type I IFN paracrine activity in our macrophage cultures. Conditioned medium (CM) collected from U937 cells stimulated for 1 h with 98-10K chitosan failed to induce STAT-1 or STAT-2 activation whereas 24 h-CM was able to specifically induce STAT-1 and STAT-2 phosphorylation in U937 cells, to a similar extent as CM from cells stimulated with IFN-a/b (Fig. 3A and B) . Neutralization of IFN-b, but not IFN-a with blocking antibodies suppressed the ability of the 98-10K chitosan to induce STAT-2 phosphorylation (Fig. 3CeE) and to stimulate IL-1ra and CXCL10 release (Fig. 3F and  G) . Neutralization of IFN-b had no effect on IL-1b release (Fig. 3H) . These data demonstrated that IFN-b is a paracrine factor induced by low doses of 98-10K chitosan that induces de novo STAT-1/STAT-2 activation and enhances CXCL10 and IL-1ra secretion.
It was previously reported that PGE 2 can inhibit IFN-a/b secretion, suggesting that the inflammasome serves as a feedback loop to shut down the type I IFN response in infected cells [26] . However, to our knowledge, it has never been reported that a biomaterial can induce this same feedback loop. U937 cells challenged with both 98-10K chitosan and increasing doses of PGE 2 showed that high doses of PGE 2 attenuated the ability of 98-10K chitosan to induce STAT-2 phosphorylation (Fig. 3D and E), CXCL10 production (Fig. 3F) and IL-1ra production (Fig. 3G) . PGE 2 showed biphasic effects on IL1b release in chitosan-stimulated cells, where the lowest dose of PGE 2 (0.1 mg/mL) potentiated IL-1b release, and the highest dose of PGE 2 (10 mg/mL) suppressed the effects of chitosan on this cytokine (Fig. 3H) . Altogether, our data showed that chitosan elicited a type 1 IFN response by inducing IFN-b release, which was necessary and sufficient to induce CXCL10 and enhance IL-1ra production. Induction of the type 1 IFN response was suppressed by PGE 2 and mutually exclusive of chitosan-induced inflammasome activation.
Lysosomal rupture is critical for chitosan-elicited type 1 IFN response and inflammasome activation
Recent work reported a linear relationship between IFN-a/b production and early phagosomal rupture induced by Mycobacterium tuberculosis [27] . Others have also suggested lysosomal escape to be necessary for activation of the inflammasome by chitosan [5] . Some forms of endocytosed chitosan were shown to escape the lysosome through a proton-sponge effect. Due to chitosan's relatively high pKa value, 6.5, chitosan primary amines become protonated in the acidifying lysosomal lumen, leading to the accumulation of chloride ions and water. Subsequent lysosomal swelling results in the release of chitosan in the cytoplasm [28] . We therefore examined whether the chitosan-induced type 1 IFN response was dependent on lysosomal acidification. Following stimulation with Rhodamine Isothiocyanate-conjugated 98-10K chitosan (98-10K-RITC), we found that inhibiting lysosomal acidification using chloroquine or bafilomycin prevented the cytosolic diffusion of RITC-chitosan, and instead, the RITC-chitosan was confined to intracellular and extracellular vesicles (Fig. 4A) . Furthermore, blockage of lysosomal acidification not only suppressed the effects of chitosan on inflammasome activation (IL-1b and PGE 2 , Fig. 4B ), it also suppressed the type 1 IFN cytokine response (IL-1ra and CXCL10, Fig. 4B ). Suppression of the type I IFN response to chitosan was more sensitive to bafilomycin which blocks the proton pump than chloroquine which impedes acidification through a buffering action (Fig. 4B) . These findings altogether confirmed that functional lysosomes were required not only for chitosan to activate the inflammasome and drive IL-1b release, but also to trigger the type 1 IFN response that promoted IL-1ra and CXCL10 release.
Our findings suggested that lysosomal rupture induced by chitosan is an essential initiating event of the type I IFN response. Lysosomal rupture is expected to trigger an autophagy response which can be measured by increased expression of LC3-II, the lipidated form of LC3 associated with newly formed autophagosomes [29] . We found that 98-10K chitosan induced LC3-II expression relative to b-actin in a dose-dependent manner ( Fig. 4C and D) . However, autophagy is a dynamic process and increased LC3-II could be explained by a net increase in autophagosome formation, or to an inhibition in autophagy flux. Blockage of autophagy flux with bafilomycin or chloroquine led to LC3-II accumulation that was not further enhanced by increasing doses of chitosan (Fig. 4C and D) . These data refuted the hypothesis that chitosan induces a net increase in autophagosome formation. Instead, these data suggested that chitosan created defective lysosomes that were incapable of fusing with autophagosomes, which led to slowed autophagy flux and higher LC3-II levels in chitosantreated cells. We next tested the hypothesis that lysosomal disruption is specific to chitosans that induce a type I IFN response. Intact lysosome levels in U937 cells, as measured by fluorescence intensity of cells loaded with LysoTracker, an acidotropic dye, were significantly decreased in macrophages stimulated with the 98-10K chitosan, and with the positive control LLoME (which induces lysosomal membrane rupture), but not with the 80-10K-R chitosan, a chitosan that failed to stimulate any cytokine responses (Fig. 5A and B) .
To provide further evidence that chitosan 98-10K, but not 80-10K-R, induces lysosomal rupture, we looked at the distribution of galectin-3 in chitosan-stimulated macrophages. Galectin-3 and galectin-8 have been identified as cytosolic lectins that can sense and target vesicles damaged by intracellular pathogens through the interaction with glycoproteins that are normally inside the lysosome [30, 31] . We hypothesized that galectin-3 colocalizes with the 98-10K-RITC chitosan, but not with the RITC-conjugated 80-10K-R (80-10K-R-RITC) chitosan, in a time-dependent manner. In unstimulated cells, galectin-3 was diffuse in the cytosol (Fig. 5C) . We observed an accumulation of galectin-3 that colocalized with large punctated RITC-chitosan (Galectin-3/RITC-chitosan structures, "GCS") when macrophages were stimulated with the 98-10K-RITC chitosan, but not with the 80-10K-R-RITC chitosan (Fig. 5C and  D) , suggesting the lysosomes were specifically ruptured by the 98-10K chitosan. Significant levels of GCS were observed at 10 and 18 h post-stimulation with the 98-10K chitosan (Fig. 5D) . Formation of these GCS was dependent on lysosomal acidification, confirming that 98-10K chitosan ruptured lysosomes through a proton spongedependent mechanism (Fig. 5D) . Consistent with our previous observation suggesting that autophagosome accumulation was a result of chitosan-mediated lysosomal disruption (Fig. 4C and D) , we found that cells stimulated with the 98-10K-RITC, but not 80-10K-R-RITC, showed accumulated LC3 punctates that either remained in the cytosol (Fig. 5E ), or colocalized with GCS (Fig. S6) . This altogether indicates that the differential capacity of the chitosans to elicit a type 1 IFN response or activate the inflammasome depends on the severity of lysosomal disruption once internalized.
Discussion
This study reports that a narrow range of chitosans (3e10 kDa, 98% DDA; 10 and 190 kDa, 80% DDA, block-acetylated) at low doses escape the lysosome and stimulate a delayed IFN-b paracrine response leading to STAT-1 and STAT-2 phosphorylation, de novo CXCL10 expression, and enhanced IL-1ra production. Our data suggest that the unique ability of selected chitosans at certain doses to induce this type 1 IFN response is related to their capacity to disrupt lysosomes as long as they do not induce significant inflammasome activation and cell death. Higher doses of chitosan, especially the 98% DDA chitosans that have greater neutral insolubility, were shown to induce inflammasome activation as marked by an IL-1b and PGE 2 response. McNab et al. recently proposed a model whereby macrophage infection by intracellular pathogens induces IL-1ra production through a IFN-a/b response that can compete and suppress the inflammasome mediator IL-1b, until excessive inflammasome activation produces PGE 2 release which suppresses IFN-a/b secretion [26] . Here, we demonstrate that like intracellular pathogens, at those concentrations that activate the inflammasome, chitosan particles induced high levels of PGE 2 , which suppressed chitosan-mediated STAT-1/STAT-2 activation and CXCL10 release. Chitosan's ability to induce the type 1 IFN response was influenced by DDA, molecular weight and level of GlcNAc clustering. At 98% DDA, activation of the inflammasome was attenuated by decreasing molecular weight, which increases chitosan neutral-solubility and potentially limits the mass of chitosan internalized per phagosome. At 80% DDA, only the block-acetylated chitosans above 10 kDa stimulated a type 1 IFN response also suggesting that part of the requirements for chitosan to induce type I IFNs may depend on a minimal quantity of glucosamine chains (i.e., 3000 Da of consecutive glucosamine monomers) to be taken up by the phagosome.
In this work, we show that chitosan-mediated type 1 IFN response and inflammasome activation were mutually exclusive. Although these cytokine responses have been described in separate reports [4, 5, 32] , our findings contribute significant insights on how these specific cytokine responses are linked, and more importantly how they are differentially elicited as a function of chitosan properties or dosage. For instance, the type 1 IFN response, which promotes IL-1ra and CXCL10 release, was restricted to specific chitosans applied at low doses. At higher doses, this response was abrogated and instead led to inflammasome activation. These novel findings suggest the possibility that chitosan dose and structural properties are tunable features that can be used to elicit or avoid specific macrophage immune responses to chitosan-based biomedical devices.
Our data showing critical effects of chitosan dose in vitro raise the important question on the potential effect of chitosan dose in vivo. Chitosans as micro-or nanoparticles were previously introduced in vivo in mice, rabbits, or sheep, at single or total dose that varied from 0.1 to 7 mg [32e38]. Interestingly, these chitosan doses in vivo were identified in our current study as inducing macrophage inflammasome activation in vitro. However, there are important differences between the in vitro and in vivo setting which likely influence macrophage responses to chitosan. In our in vitro model, chitosan is delivered at a constant dose directly to macrophages for 24 h. This is different from the in vivo setting, where chitosan is delivered to tissues that contain variable levels of resident macrophages, recruited monocytes and other leukocytes, and chitosan concentration gradually decreases over time [39] . Little is known on the effect of chitosan dose on in vivo responses, mainly because we currently lack quantitative tools such as immunodetection or direct monitoring techniques to accurately measure chitosan concentration in vivo. However, our findings show that macrophage responses are highly sensitive to dose and suggest that chitosans delivered at doses capable of inducing macrophage inflammasome activation in vitro may become cleared or dispersed enough to lead to lower local chitosan concentrations, which may instead lead to a type 1 IFN response. This scenario is in fact supported by the observation that relatively high doses of chitosan adjuvant, 1 mg, elicit specific in vivo immune responses to H1 antigen (anti-H1 IgG2a production), but only in mice with a functional IFN-b receptor [32] . Our study highlights that in addition to chitosan structure, dose is another critical factor that can influence macrophage response to chitosan. Measuring the effects of chitosan dose and structure in vivo will be challenging and important to pursue in future studies.
Several studies have suggested that chitosan could be used to drive specific macrophage responses, such as M2 activation, that could be beneficial for wound repair [3, 6, 7, 10, 11] . However, identifying which chitosans lead to these responses has been a significant challenge due conflicting information in the literature. Indeed, chitosans with DDA between 80 and 95%, or varying molecular weights, have been reported in separate studies to either elicit either pro-[4e6, 8, 11, 13, 40, 41] , or anti-inflammatory macrophages responses [3, 6, 7, 10, 11] . These inconsistencies may stem from incomplete chitosan characterization [4, 5, 7, 13, 40] , the different chitosan doses used across the different studies and the exclusive investigation of either only pro-or anti-inflammatory responses, which makes data interpretation difficult. Nonetheless, our data have revealed an interesting influence of chitosan solubility state on macrophage inflammatory responses. Based on our data, we predict that chitosans that are chemically modified to have higher neutral-solubility (i.e. PEGylated chitosan), and chitosans that induce strong PGE 2 will have little capacity to induce IFN-b, CXCL10 and higher IL-1ra release. Our study further predicts that chitosans that are more insoluble, highly deacetylated, and have a particle size amenable to phagocytosis will have a greater capacity to activate the inflammasome. Our findings bridge an important gap in the literature in identifying which chitosans will lead to inflammasome activation in macrophages, and which ones will not.
Chitosan likely activates immune cells through multiple mechanisms that are mostly unknown. Currently, there are two identified mechanisms involved in chitosan-mediated immune activation, the cGAS-STING/type 1 IFN pathway and NLRP3/ inflammasome activation/IL-1b release [4, 5, 32] . We hypothesize that lysosomal rupture following chitosan phagocytosis is an essential initiating event that precedes both the cGAS-STING pathway and the inflammasome, and downstream cytokine responses. Firstly, our data show that the induction of CXCL10 secretion (i.e. 10 h, [6] ) was paralleled by a time-dependent increase in lysosomal disruption (Figs. 4A, 5C and D) . Lysosome rupture releases lysosomal contents, including proteases and glycosidases to the cytosol; after release to the cytosol some lysosomal proteases (cathepsins) are known to exert downstream effects on mitochondria [42] . Secondly, our data show that agents that block lysosomal acidification are sufficient to prevent chitosan-mediated cytokine responses, as bafilomycin prevented chitosan at different doses from inducing CXCL10 (Fig. 4B) or IL-1b release (Fig. 4B, [5] ).
Our data are consistent with the notion that mild levels of lysosomal disruption induced by chitosan lead to a type 1 IFN response, where paracrine IFN-b leads to intensified release of IL-1ra that can suppress low-level inflammasome induction of PGE 2 [26] . Conversely, chitosans that induced an overwhelming release of lysosomal content led to robust activation of the inflammasome and IL-1b secretion, which can out-compete extracellular IL-1ra leading to COX-2 activation, PGE 2 generation, and suppression of type 1 IFN secretion [26] . Mitochondrial-derived reactive oxygen species were suggested to be involved in the type 1 IFN response and inflammasome activation induced by a chitosan characterized as having 75e90% DDA and 150e400 kDa [5, 32] ; this chitosan preparation induced mitochondrial changes as early as 3 h after stimulation, which was followed by IFN-b release after 24 h [32] . Because in that previous study, the role of bafilomycin was not investigated, it would be interesting to test whether bafilomycin can prevent chitosan from inducing early mitochondrial changes in macrophages.
It is interesting to note that LC3-II co-localized with the GCS (Fig. S6) . During bacterial intracellular infection, galectin-3, 8 and 9 detect damaged vesicles and galectin-8 targets them for autophagy as a means to restrict pathogen proliferation following infection [30, 31] . Our results suggest that galectin-3 can sense vesicles damaged by chitosan and also provide evidence that chitosandisrupted lysosomes are targeted to autophagosomes.
This study was conducted in a U937 macrophage model which was necessary for extensive screening of the chitosan library. The U937 cell model was chosen over primary macrophages partly because of the large numbers of cells required (>50 million cells per screen, and 4 distinct screening assays for N ¼ 4), and partly because primary macrophages are known to exhibit donor-specific responses meaning primary cells would have required many replicates from potentially more than a single donor. It is important to note that U937 cells are transformed monocytic cells, and require PMA to terminally differentiate to macrophages. PMA enhances the expression of several genes involved in macrophage differentiation and function, including COX-2 and IRF-3/IRF-7 [43, 44] , which are critical for PGE 2 generation and type 1 IFN gene expression, respectively [43, 44] . PMA also stimulates autophagy, phagocytosis and lysosomal activity [45, 46] , which are shown here and in previous studies to be important for chitosan-elicited cytokine responses [4, 6] . Hence, PMA addition has an influence on macrophage responses to chitosan, especially since we previously showed that PMA-priming was necessary for chitosan (82% DDA, 132 kDa, block-acetylated) to induce CXCL10 expression in nonpolarized human primary macrophages [6] . Our data now allow us to focus on specific chitosans for further analysis in primary cells and in vivo. Nevertheless, our findings are highly consistent, in terms of chitosan properties and concentration used, with previous studies showing that 80% DDA high molecular weight chitosans can activate the inflammasome in primary macrophages or elicit type 1 IFN responses in primary dendritic cells [4, 5, 32] . It is possible that chitosan may only trigger a type I IFN response in vivo when phagocytosed by activated macrophages. Primary dendritic cells produced in vitro by extended culture in GM-CSF were able to respond to a partly acetylated chitosan with IFN-b release [32] . In sum, these data suggest that to elicit type 1 IFN response in vivo, chitosan requires not only the right optimal structure and dose, but may also require tissue niches where GM-CSF or other cell polarization factors are present.
We found that low chitosan doses stimulate macrophages to release IL-1ra through paracrine type 1 IFN activity. In addition to using chitosan to induce type 1 IFNs for effective adjuvant effects in vaccines [32, 37] , our work suggests that chitosan-mediated type 1 IFN responses may have other important therapeutic benefits in the context of regenerative medicine. Type 1 IFNs play important role in skin reepithelization following wounding [47] . Others have also shown that type 1 IFN promotes IL-1ra expression in liver tissues to yield a protective effect against fibrosis [48] . In osteochondral repair, IL-1ra is the physiological inhibitor of IL-1b, an important cytokine that contributes to the development of cartilage breakdown and osteoarthritis [49] . Although intra-articular type I IFN is detected in joints with chronic rheumatoid arthritis [50] , IFN-b was previously tested in several clinical trials as a therapeutic to suppress joint inflammation [51] . Further work is needed to determine whether chitosan can be used to induce therapeutic type 1 IFN responses that are clinically beneficial for tissue engineering and wound repair.
Conclusion
The chitosan library generated in this study allowed us to identify the structural motifs required for chitosan to stimulate distinct cytokine responses in human macrophages. The minimal motif identified was 3 kDa of fully deacetylated chitosan, which is likely to be represented in the block 80% DDA 10 kDa and 190 kDa preparations. Specific chitosan preparations (10 or 190 kDa, blockacetylated 80% DDA; 3, 5 or 19 kDa, 98% DDA) stimulated two mutually exclusive cytokine responses as a function of chitosan dose which produced different levels of lysosomal disruption. Low chitosan doses induced mild lysosomal disruption to elicit a type 1 IFN response, which involved paracrine IFN-b activity and STAT-1/ STAT-2 phosphorylation that led to IL-1ra and CXCL10 release. High levels of lysosomal disruption induced by higher chitosan doses activated the inflammasome which led to increased IL-1b, and PGE 2 release that suppressed the type 1 IFN response. These findings provide new advances in our understanding of the immunological properties of chitosan in macrophages, which will contribute to a better use of chitosan in widespread biomedical applications.
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